Gene Therapy Patient Pipeline Builds, But Slowly, In Q2

Bluebird, Vertex and Sarepta are starting to see some commercial gene therapy traction and expect momentum to pick up in the second half, while hemophilia remains a challenging area. 

gene therapy
gene therapies slowly picked up momentum in Q2 • Source: Shutterstock

Some gene therapy manufacturers, like bluebird bio, Vertex Pharmaceuticals Incorporated and Sarepta Therapeutics, Inc., are beginning to see a ramp up in their commercial businesses and reported an expanding pipeline of patients beginning the process to start treatment in the second quarter. But the number of patients treated with new gene therapies remains limited and companies focused on hemophilia, including CSL Limited and BioMarin Pharmaceutical Inc., have continued to experience slow uptake.

Key Takeaways
  • With several gene therapy launches under way, manufacturers are gaining valuable commercial experience.
  • Sarepta stands out as an early commercial success with Elevidys for DMD, while...

Of the handful of companies that have launched new gene therapies during the last two years, Sarepta stands out for its early commercial win with Elevidys (delandistrogene moxeparvovec), a gene...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Gene Therapies

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Verve Moves Toward Lilly Opt-In For PCSK9 Program With Phase Ib Results

 

The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.

More from Advanced Therapies

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By 

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Gilead Pipeline Progress Offsets Oncology Sales Slowdown

 

Sales of the company’s approved cancer therapies were weaker or down, but Trodelvy is likely to see a label expansion and cell therapies are making progress.